Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Outlook and Growth Opportunities 2025

Summary

According to APO Research, the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for GLP-1 Agonists for the Treatment of both Diabetes and Obesity is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.

The Asia-Pacific market for GLP-1 Agonists for the Treatment of both Diabetes and Obesity is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the GLP-1 Agonists for the Treatment of both Diabetes and Obesity market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.

The Europe market for GLP-1 Agonists for the Treatment of both Diabetes and Obesity is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the GLP-1 Agonists for the Treatment of both Diabetes and Obesity market include Novo Nordisk and Eli Lilly etc. In 2024, the top three vendors accounted for approximately % of the market revenue.

This report presents an overview of global market for GLP-1 Agonists for the Treatment of both Diabetes and Obesity, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of GLP-1 Agonists for the Treatment of both Diabetes and Obesity, also provides the value of main regions and countries. Of the upcoming market potential for GLP-1 Agonists for the Treatment of both Diabetes and Obesity, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the GLP-1 Agonists for the Treatment of both Diabetes and Obesity revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.

GLP-1 Agonists for the Treatment of both Diabetes and Obesity Segment by Company


Novo Nordisk

Eli Lilly

GLP-1 Agonists for the Treatment of both Diabetes and Obesity Segment by Type


Tirzepatide

Semaglutide

Liraglutide

GLP-1 Agonists for the Treatment of both Diabetes and Obesity Segment by Application


Retail Pharmacies

Hospital and Clinic

Other

GLP-1 Agonists for the Treatment of both Diabetes and Obesity Segment by Region


North America


United States

Canada

Mexico

Europe


Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific


China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America


Brazil

Argentina

Chile

Middle East & Africa


Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the GLP-1 Agonists for the Treatment of both Diabetes and Obesity key companies, revenue, market share, and recent developments.
3. To split the GLP-1 Agonists for the Treatment of both Diabetes and Obesity breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions GLP-1 Agonists for the Treatment of both Diabetes and Obesity market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify GLP-1 Agonists for the Treatment of both Diabetes and Obesity significant trends, drivers, influence factors in global and regions.
6. To analyze GLP-1 Agonists for the Treatment of both Diabetes and Obesity competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of GLP-1 Agonists for the Treatment of both Diabetes and Obesity and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GLP-1 Agonists for the Treatment of both Diabetes and Obesity.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity industry.
Chapter 3: Detailed analysis of GLP-1 Agonists for the Treatment of both Diabetes and Obesity company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of GLP-1 Agonists for the Treatment of both Diabetes and Obesity in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of GLP-1 Agonists for the Treatment of both Diabetes and Obesity in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit. Show more